KALV · KalVista Pharmaceuticals, Inc.
$27.00
+0.00 (+0.00%)
At close · Jun 12
Market Cap
$1.44B
Shares
53.24M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$27.00
Open$27.00
Day$27.00–27.00
52W$9.83–27.00
Avg vol 30d3.0M
Short int6.8M · 12.9% float · 2.0d
Short vol75%
Last earningsMar 25, 2026
DataJan 2020–Jun 2026
Filing10-Q · May 14
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Moderate
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+59%
above
Price vs 50-day avg
+11%
above
RSI (14)
75
overbought
MACD trend
Negative
52-week position
100%
near high
Momentum
relative strength
1-month return
+1%
trailing
6-month return
+80%
trailing
YTD return
+67%
this year
Relative strength
+70%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $24 › 200d $17 — 50d above 200d
Institutional flow
Distributing
24 of 184 funds reported for Jun 30 · net -636.6K sh shares · +1 new
Insider flow
Distributing
Net -$1.8M over 90 days · 100% sells
Short interest
Falling
12.85% of float · ▼ -43.2% MoM · 2.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
184 holders — near 3-yr high, broad support
Fundamentals
Revenue growth
0%
Y/Y
EPS growth
+45%
Y/Y
Free cash flow
$-83.3M
Balance sheet
$57.1M
net cash
Quant / Vol
risk profile
Volatility
72%
annualized · 1-yr
Max drawdown
−33%
past year
ATR
0.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+59%
Bullish
Price vs 50-day avg
+11%
Bullish
RSI (14)
75
Bearish
MACD trend
Negative
Bearish
52-week position
100%
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $24 › 200d $17 — 50d above 200d
Institutional flow
Distributing
24 of 184 funds reported for Jun 30 · net -636.6K sh shares · +1 new
Insider flow
Distributing
Net -$1.8M over 90 days · 100% sells
Short interest
Falling
12.85% of float · ▼ -43.2% MoM · 2.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
184 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $10
Now $27 · 100%
52-wk high $27
vs 200-day avg +59%
vs 50-day avg +11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Global net product revenue of EKTERLY (sebetralstat) | $49.1M | eight months ended December 31, 2025 | — |
| patient start forms received in the US | 1,318 | through December 31, 2025 | — |
| unique prescribers activated in the US | 580 | through December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KALV
this stock
KalVista Pharmaceuticals, Inc.
|
$1.44B | +67.2% | -21.3% | — | 12.9% |
|
ONC
BeOne Medicines Ltd.
|
$471.01B | +7.3% | +22179.2% | 958.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.57B | +8.2% | +46.2% | 28.4 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.95B | -9.8% | +20.8% | 16.3 | 3.3% |
|
ARGX
Argenx SE
|
$55.61B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KALV | +0.2% | +0.9% | +80.0% | +0.5% | +67.2% |
| SPY | +0.6% | -0.9% | +9.7% | -2.0% | +8.8% |
| vs SPY | -0.4% | +1.8% | +70.4% | +2.4% | +58.4% |